AAGH · America Great Health · Financials
Substantial doubt about the company's ability to continue as a going concern.
“These factors create substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.”View the 10-Q filed Aug 6, 2026
2 customers — 22% of revenue (nine months ended March 31, 2026)
“For the nine months ended March 31, 2026, two major customers accounted for approximately 22% each of our total revenue during the period.”
One customer — 22% of revenue (nine months ended March 31, 2026)
“For the nine months ended March 31, 2026, two major customers accounted for approximately 22% each of our total revenue during the period.”
One customer — 13% of revenue (three months ended March 31, 2026)
“For the three months ended March 31, 2026, three major customers accounted for approximately 13%, 10% and 10% respectively of our total revenue during the period.”
2 customers — 10% of revenue (three months ended March 31, 2026)
“For the three months ended March 31, 2026, three major customers accounted for approximately 13%, 10% and 10% respectively of our total revenue during the period.”
One customer — 11% of revenue (nine months ended March 31, 2025)
“For the nine months ended March 31, 2025, only one major customer accounted for approximately 11% of our total revenue during the period.”
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $363.33K | $391.74K | $294.67K | $204.31K | $104.65K | $195.67K | $5474 | $0 | $0 | $0 | $0 | $43.37K | — | $6627 | $4500 | |
| $114.17K | $52.62K | $124.92K | $35.72K | $1.59M | $144.32K | $3369 | $0 | $0 | $0 | $0 | $59.31K | — | — | $456 | |
| $249.16K | $339.12K | $169.75K | $168.59K | -$1.48M | $51.35K | $2105 | $0 | $0 | $0 | $0 | -$15.94K | — | $6627 | $4044 | |
| — | 86.57% | 57.61% | 82.52% | -1417.9% | 26.24% | 38.45% | — | — | — | — | -36.76% | — | 100% | 89.87% | |
| — | — | — | — | — | — | — | — | — | — | $122.68K | — | — | — | — | |
| $559.71K | $671.19K | $856.62K | $657.23K | $3.16M | $294.91K | — | — | — | — | — | — | — | — | — | |
| $631.34K | $722.06K | $952.45K | $661.23K | $3.25M | $294.91K | — | — | — | $48.37K | $0 | — | — | — | — | |
| $1.47M | — | — | — | — | $294.91K | $48.26K | $46.77K | $58.15K | $48.37K | — | — | — | — | — | |
| -$382.18K | -$382.94K | -$782.7K | -$492.64K | -$4.73M | -$243.56K | -$46.15K | -$46.77K | -$58.15K | -$48.37K | — | — | — | — | — | |
| — | -97.75% | -265.62% | -241.13% | -4523.83% | -124.47% | -843.09% | — | — | — | — | — | — | — | — | |
| $365.39K | $338.35K | $443.72K | $319.71K | $190.92K | $20.04K | $4965 | $4494 | $0 | — | — | — | — | -$1426 | — | |
| $30 | $46 | $61 | $26 | $5 | $0 | — | — | — | — | — | — | — | — | — | |
| $1.02M | -$338.31K | -$443.66K | -$284.7K | -$190.84K | -$25.49K | -$4965 | -$17.47K | -$437 | $0 | — | — | — | — | — | |
| $0 | — | — | $0 | $0 | -$5450 | $0 | -$966 | -$437 | $0 | — | — | — | — | — | |
| $638.91K | -$721.24K | -$1.23M | -$777.34K | -$4.92M | -$269.05K | -$51.12K | -$64.24K | -$58.59K | -$48.37K | $0 | — | — | — | — | |
| — | — | — | — | — | $0 | $800 | $800 | $800 | $0 | $0 | — | — | — | — | |
| $639.11K | -$719.12K | -$1.22M | -$761.42K | -$4.92M | -$269.05K | -$51.92K | -$65.04K | -$59.39K | -$967.03K | -$1.14M | -$660.09K | -$353.28K | -$108.8K | -$56.26K | |
| — | -183.57% | -414.22% | -372.68% | -4706.19% | -137.5% | -948.41% | — | — | — | — | -1522.01% | — | -1641.77% | -1250.24% | |
| -$200 | -$2123 | -$5791 | -$15.92K | -$58.78K | $0 | — | — | — | $0 | -$9942 | -$15.56K | — | — | — | |
| -$735.46K | — | — | -$761.42K | -$4.87M | -$269.05K | — | — | — | — | -$1.14M | -$644.54K | — | — | — | |
| $641.83K | -$719.56K | -$1.22M | -$760.76K | -$4.87M | -$269.05K | — | — | — | — | — | — | — | — | — | |
| USD/shares | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 21.14B | 21.12B | 21.09B | — | 20.44B | 20.24B | 20.24B | 20.24B | 20.18B | 20.05B | — | — | — | — |
| shares | — | 21.14B | 21.12B | 21.09B | — | 20.44B | 20.24B | 20.24B | 20.24B | 20.18B | 20.05B | — | — | — | — |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Long-term debt, including current maturities | 2026-03-31 | USD 2,423,349 | 10-Q filed 2026-08-06 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
| Operating lease liabilities | 2026-03-31 | USD 9,086 | 10-Q filed 2026-08-06 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
| Short-term borrowings | 2026-03-31 | USD 692,020 | 10-Q filed 2026-08-06 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 250 similar-size Biotechnology companies (of 560 listed).